The Peptide Addict applies a single methodology to everything it publishes. It has three parts: the four lenses, the evidence ladder, and the scorecard.
The four lenses
Every major article is analyzed through four separate lenses.
1. Evidence
What human evidence actually exists? How many trials, how large, how rigorous, how replicated? Animal data and mechanistic rationale are flagged separately — they are never presented as proof of human outcomes.
2. Safety
What do we know about side effects, interactions, and long-term risk? What remains uncertain? Are there contraindications that the market is not talking about?
3. Legal / access reality
Is the compound an approved drug? A compounded medication? A research-use-only chemical? An unapproved gray-market substance? Each category has different implications for quality, legal exposure, and access.
4. Market integrity
Who profits from the current narrative? Where are incentives likely distorting the information? Which claims are driven by evidence and which are driven by commerce?
The evidence ladder
When evaluating any claim, The Peptide Addict applies a strict hierarchy. The lower on the ladder a source falls, the stronger the caveats in the published article.
- Regulatory status, approved labeling, and official warnings
- Meta-analyses and systematic reviews in humans
- Randomized controlled trials in humans
- Other human trials and observational data
- Mechanistic human biomarker data
- Animal studies
- In vitro studies
- Expert opinion
- Anecdotes, forums, and social media
- Vendor marketing
House rule: Marketing copy never counts as evidence. Community reports are question leads, not proof.
The Peptide Addict Scorecard
Every major article includes a visible scorecard across six dimensions:
- Evidence strength — how strong is the overall case?
- Human data depth — how much human evidence exists, and how rigorous?
- Safety certainty — how well understood are the risks?
- Regulatory clarity — how clear is the legal and access picture?
- Access complexity — how difficult or risky is it to obtain?
- Hype gap — how far public enthusiasm exceeds the quality of evidence
Each dimension is scored 1–5 and labeled Very Low through Very High. The hype gap is the signature concept: a compound can have high popularity, low human data, and therefore a high hype gap — meaning the conversation about it is running well ahead of the evidence.
What this methodology protects against
- Presenting mechanism as proof of outcome
- Collapsing the distinction between animal data and human data
- Treating regulatory approval and gray-market availability as equivalent
- Importing vendor marketing into editorial reasoning
- Inflating preclinical findings into clinical recommendations
See also
- Editorial Policy — the seven principles we publish under
- How to Evaluate a Peptide Vendor — the methodology applied to vendors
- The Beginner’s Guide to Peptides — the framework applied end-to-end